Holen Sie sich die Stockscreener-App
26.14
1.69%
-0.43
Schlusskurs vom Vortag:
$26.57
Offen:
$26.61
24-Stunden-Volumen:
443.14K
Relative Volume:
0.26
Marktkapitalisierung:
$16.08B
Einnahmen:
$2.62B
Nettoeinkommen (Verlust:
$966.70M
KGV:
17.42
EPS:
1.5004
Netto-Cashflow:
$1.09B
1W Leistung:
-3.47%
1M Leistung:
-13.02%
6M Leistung:
-6.11%
1J Leistung:
+30.86%
1-Tages-Spanne:
$26.06
$26.84
1-Wochen-Bereich:
$26.06
$28.16
52-Wochen-Spanne:
$17.23
$35.43
Genmab Adr Stock (GMAB) Company Profile
Compare GMAB vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GMAB
Genmab Adr
|
26.16 | 16.34B | 2.62B | 966.70M | 1.09B | 1.5004 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.81 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.24 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
705.49 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.82 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.10 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Genmab Adr Stock (GMAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-02 | Eingeleitet | Wells Fargo | Overweight |
| 2026-02-17 | Fortgesetzt | Jefferies | Buy |
| 2026-02-17 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2025-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-04-01 | Herabstufung | Bernstein | Mkt Perform → Underperform |
| 2025-03-11 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-02-13 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-08 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-09-04 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-08-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-15 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-02-23 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2024-01-22 | Herabstufung | Citigroup | Neutral → Sell |
| 2023-12-06 | Hochstufung | UBS | Neutral → Buy |
| 2023-11-10 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2023-11-08 | Hochstufung | DNB Markets | Sell → Buy |
| 2023-10-18 | Eingeleitet | Exane BNP Paribas | Underperform |
| 2023-09-06 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-24 | Eingeleitet | BTIG Research | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-31 | Eingeleitet | UBS | Neutral |
| 2023-05-12 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-12-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-11-14 | Eingeleitet | William Blair | Mkt Perform |
| 2022-11-11 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2022-05-02 | Eingeleitet | Cowen | Market Perform |
| 2022-03-16 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-31 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-12-01 | Eingeleitet | Berenberg | Sell |
| 2021-09-16 | Herabstufung | Jefferies | Buy → Hold |
| 2021-09-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-08-24 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-04-20 | Eingeleitet | Deutsche Bank | Buy |
| 2021-01-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-09-23 | Herabstufung | Bryan Garnier | Neutral → Sell |
| 2020-09-08 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-06-25 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2020-04-23 | Eingeleitet | Credit Suisse | Outperform |
| 2020-02-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-12-12 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2019-09-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-09-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-08-12 | Eingeleitet | Guggenheim | Buy |
| 2019-08-12 | Eingeleitet | Morgan Stanley | Overweight |
| 2019-08-12 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Genmab Adr Aktie (GMAB) Neueste Nachrichten
First Trust Advisors LP Sells 82,922 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab (GMAB) Upgraded to Strong Buy: Here's Why - MSN
Correction to Company Announcement No. 13 of March 2, 2026 - GlobeNewswire Inc.
Stocks With Rising Relative Strength: Genmab ADR - Investor's Business Daily
Genmab ADR shows improved relative strength; still shy of benchmark - MSN
Genmab ADR Shows Improved Relative Strength; Still Shy Of Benchmark - Investor's Business Daily
GENMAB A/S -SP ADR (NASDAQ:GMAB) Emerges as a Peter Lynch-Style GARP Investment - ChartMill
Genmab (GMAB) Reports 19% Revenue Growth to $3.7B in 2025 Driven by Proprietary Medicine Sales - Finviz
Genmab A/S (NASDAQ:GMAB) Given New $40.00 Price Target at HC Wainwright - Defense World
Top 3 Health Care stocks That Could Lead To Your Biggest Gains In Q1 - Sahm
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Genmab A/S (NASDAQ:GMAB) Coverage Initiated by Analysts at Jefferies Financial Group - Defense World
Genmab A/S Q4 Earnings Call Highlights - Yahoo Finance
Genmab A/S (NASDAQ:GMAB) Given Equal Weight Rating at Morgan Stanley - Defense World
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Sees Significant Decrease in Short Interest - MarketBeat
279,932 Shares in Genmab A/S Sponsored ADR $GMAB Bought by Cibc World Market Inc. - MarketBeat
Is the Options Market Predicting a Spike in Genmab Stock? - TradingView
H.C. Wainwright Bullish on Genmab A/S (GMAB) on Robust Sales for DARZALEX - Finviz
Envestnet Asset Management Inc. Purchases 60,336 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat
RFG Advisory LLC Takes $1.30 Million Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Where is Genmab A/S (GMAB) Headed According to Wall Street? - Finviz
Oppenheimer Asset Management Inc. Acquires 61,311 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab A/S (NASDAQ:GMAB): A GARP Case Study in Affordable Biotech Growth - ChartMill
Federated Hermes Inc. Makes New Investment in Genmab A/S Sponsored ADR $GMAB - MarketBeat
What is HC Wainwright’s Estimate for Genmab A/S Q4 Earnings? - Defense World
What is HC Wainwright's Estimate for Genmab A/S Q4 Earnings? - MarketBeat
EPKINLY Trial Results Prompt Price Target Cut for Genmab (GMAB) - Finviz
HC Wainwright Boosts Earnings Estimates for Genmab A/S - MarketBeat
GENMAB A/S (NASDAQ:GMAB) Stands Out as a Peter Lynch-Style GARP Investment - Chartmill
Genmab A/S (NASDAQ:GMAB) Shares Gap DownHere's What Happened - MarketBeat
GENMAB A/S -SP ADR (NASDAQ:GMAB) Combines Strong Growth with Bullish Technical Formation - Chartmill
GENMAB A/S (NASDAQ:GMAB) Presents a Compelling Blend of Strong Fundamentals and Bullish Technicals - ChartMill
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Alkermes Stock Earns Technical Rating Upgrade - Investor's Business Daily
Genmab A/S (GMAB) Shares Gain Analyst Support as Deutsche Bank Sees Oncology Upside - Finviz
Ascendis Pharma ADR shows rising price performance with jump to 83 RS rating - MSN
Genmab A/S (GMAB): A Bull Case Theory - Finviz
Oric Pharmaceuticals Stock Sees Healthy RS Rating Jump To 80 - Investor's Business Daily
Biotech Stocks To Watch And Pharma Industry News - Investor's Business Daily
Eagle Global Advisors LLC Buys 34,175 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab ADR Joins Rank Of Stocks With RS Ratings Over 90 - Investor's Business Daily
Genmab A/S (NASDAQ:GMAB) Hits New 52-Week HighTime to Buy? - MarketBeat
Genmab A/S (OTCMKTS:GNMSF) Reaches New 1-Year HighShould You Buy? - MarketBeat
Moderna Stock Gets Healthy Relative Strength Rating Jump - Investor's Business Daily
Genmab (GMAB) Upgraded to Buy: Here's What You Should Know - MSN
Quoin Pharm ADR clears technical benchmark, hitting 90-plus RS rating - MSN
Genmab A/SAmerican Depositary Shares (NQ: GMAB - FinancialContent
Genmab A/S (OTCMKTS:GNMSF) Reaches New 52-Week HighHere's What Happened - MarketBeat
Stocks To Watch: Immunocore Holdings ADR Sees RS Rating Rise To 83 - MSN
Genmab A/S (NASDAQ:GMAB) Shares Down 3.5% – Here’s Why - Defense World
Finanzdaten der Genmab Adr-Aktie (GMAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Genmab Adr-Aktie (GMAB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| GENMAB A/S | 10% Owner |
Dec 26 '25 |
Buy |
97.00 |
2,978 |
288,866 |
72,831,487 |
| GENMAB A/S | 10% Owner |
Dec 23 '25 |
Buy |
97.00 |
561,042 |
54,421,074 |
72,589,817 |
| GENMAB A/S | 10% Owner |
Dec 26 '25 |
Buy |
97.00 |
142,610 |
13,833,170 |
72,828,509 |
| GENMAB A/S | 10% Owner |
Dec 24 '25 |
Buy |
97.00 |
96,082 |
9,319,954 |
72,685,899 |
| GENMAB A/S | 10% Owner |
Dec 22 '25 |
Buy |
97.00 |
15,710 |
1,523,870 |
72,028,775 |
| GENMAB A/S | 10% Owner |
Dec 18 '25 |
Buy |
97.00 |
212,177 |
20,581,169 |
71,946,801 |
| GENMAB A/S | 10% Owner |
Dec 19 '25 |
Buy |
97.00 |
66,264 |
6,427,608 |
72,013,065 |
| GENMAB A/S | 10% Owner |
Dec 17 '25 |
Buy |
97.00 |
150,795 |
14,627,115 |
71,734,624 |
| GENMAB A/S | 10% Owner |
Dec 16 '25 |
Buy |
97.00 |
120,752 |
11,712,944 |
71,583,829 |
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):